Uterine Cancer - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 46
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: U8FC4104BEAEN
Leaflet:

Download PDF Leaflet

Uterine Cancer - Pipeline Review, Q4 2010
Uterine Cancer - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Uterine Cancer Pipeline Review, Q4 2010”, provides an overview of the Uterine Cancer therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer . “Uterine Cancer -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Uterine Cancer   .
  • A review of the Uterine Cancer    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Uterine Cancer    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • A snapshot of the global therapeutic scenario for Uterine Cancer   .
  • A review of the Uterine Cancer    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Uterine Cancer    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Uterine Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Uterine Cancer
Uterine Cancer Therapeutics under Development by Companies
Uterine Cancer Therapeutics under Investigation by Universities/Institutes
Companies Involved in Uterine Cancer Therapeutics Development
Sanofi-Aventis
DEKK-TEC, Inc.
Universities/Institutes Involved in Uterine Cancer Therapeutics Development
Uterine Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Bevacizumab + Filgrastim + Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Gemcitabine + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Bevacizumab + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Uterine Cancer - Featured News
May 28, 2008: BiPar Sciences Expands Clinical Development Of BSI-201, A Novel PARP Inhibitor, With Phase II Trial In Uterine Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 4

LIST OF TABLES

Number of Products Under Development for Uterine Cancer, 2010
Products under Development for Uterine Cancer – Comparative Analysis, 2010
Sanofi-Aventis, 2010
DEKK-TEC, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 43

LIST OF FIGURES

Number of Products under Development for Uterine Cancer, 2010
Products under Development for Uterine Cancer – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 25
Uterine Cancer - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 139 pages
Uterine Cancer - Pipeline Review, H2 2013 US$ 2,000.00 Oct, 2013 · 44 pages
Uterine Fibroids - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 41 pages
Medullary Thyroid Cancer - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 26 pages
Metastatic Breast Cancer - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 213 pages

Ask Your Question

Uterine Cancer - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: